公开(公告)号：EP1784414A2

公开(公告)日：2007-05-16

申请号：EP05808430.2

申请日：2005-08-12

申请人： The Regents of the University of California

发明人： LICINIO, Julio ,  WONG, Ma-Li ,  IRIZARRY, K.J.L., UCLA Neuropsychiatric Inst. ,  IRIZARRY, K.M., UCLA Neuropsychiatric Inst.

IPC分类号： C07H21/04 ,  C12Q1/68 ,  C12P19/34

CPC分类号： G01N33/74 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N2333/695 ,  G01N2333/72 ,  G01N2800/30 ,  G01N2800/52

摘要： The invention provides genetic means, including compositions (e.g., kits) and methods, to predict the efficacy of a treatment in depression and anxiety and to predict a patient's response to a particular a specific medication or treatment. The invention provides methods for diagnosing the presence of a psychiatric disorder or determining the outcome of a treatment for a psychiatric disorder. The invention provides methods for methods for diagnosing the presence of a psychiatric disorder in an individual by determining what corticotropin-releasing hormone receptor 1 (CRHR1) protein or transcript isoforms are expressed in an individual. The invention provides methods for diagnosing the presence of a psychiatric disorder in an individual by determining what protein or transcript isoforms are expressed in an individual wherein the protein is involved in the hypothalamic-pituitary-adrenal (HPA) axis pathway.